Trial Profile
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 10 Feb 2018 Results of a pooled analysis of NCT02918357 & NCT02611882 (n=158) in detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy, presented at the 2018 Genitourinary Cancers Symposium
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2017 New trial record